Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07306832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07306832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
May 20, 2026
Completion date
March 31, 2030
Enrollment
18 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia